Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin(TM) Investigational Treatment for Breast Cancer-Associated Lymphedema
15 oct. 2012 08h00 HE
|
Laurantis Pharma Oy; Ark Therapeutics Group plc
LONDON and TURKU, FINLAND--(Marketwire - Oct 15, 2012) - Ark Therapeutics has been selected to manufacture and supply Lymfactin™ to Laurantis Pharma under a conditional agreement...